Every intervention Outliyr has scored for nerve regeneration, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for nerve regeneration; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
26 of 85 evaluated interventions score 3.0+ out of 10 for nerve regeneration · 4 comparisons
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits nerve regeneration when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The…
Hamblin 2018 supports neurorepair mechanisms in photobiomodulation, while peripheral nerve trials remain condition-specific. The mechanism is plausible through mitochondrial support, Schwann-cell signaling, blood flow, and inflammation control. The clinical bar is higher…
Willis 2025 anchors the most relevant signal. Lion's Mane fits nerve regeneration when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling over weeks. The score stays…
Peripheral nerve pilot data and carpal tunnel adjunct use justify a moderate exploratory score, but the evidence is not as mature as OA or bone-stimulation evidence. PEMF may be worth considering as…
Nerve-regeneration support comes from stroke and brain-injury remodeling models rather than human peripheral-nerve trials. Morris 2010 supports axonal and neurological recovery signals in rats, while human evidence remains absent for injected TB-500.…
Kang et al. 2009 gives the strongest anchor. The v0 score remains because GHK-related nerve outgrowth and neuronal-protection signals exist, but mostly outside direct human GHK-Cu trials. Zhang 2018 supports neuroprotective signaling…
Whole-Body Vibration may improve local blood flow and reduce inflammation, factors that theoretically aid nerve health, yet direct regeneration outcomes remain unproven. Current studies are limited to short-term sensory improvement and lack…
Nerve regeneration is ARA-290's strongest case and the reason it scores at the top of this group. In the Phase 2b dose-ranging trial, 4 mg per day raised corneal nerve fiber area…
Support is plausible through injury repair, CRPS, radiation injury, and neurorehab studies. Kiralp 2004 reports CRPS pain and function gains after a small RCT of hyperbaric oxygen. Direct peripheral nerve regeneration outcomes…
Aerobic exercise may support nerve health indirectly through glucose control, blood flow, and neurotrophic signaling. Direct human evidence for nerve regeneration from Zone 2 specifically is limited, so this remains an exploratory…
No direct nerve-regeneration evidence was verified for EAA supplementation. The score stays below neutral.
No direct human nerve-regeneration evidence for glycine supplementation.
Nerve regeneration data are entirely preclinical for native Tβ4, but the rodent signal is consistent across stroke and traumatic brain injury models. In rat embolic stroke, Tβ4 improved neurological functional outcome and…
Russian optic-nerve use and preclinical neural protection make nerve repair a plausible research direction, but human nerve-regeneration trials remain limited.
No direct nerve-regeneration evidence. Keep below neutral until peripheral nerve or neuropathy trials exist.
GLP-1 neuroprotection research does not translate into established peripheral nerve regeneration evidence for semaglutide.
INSUFFICIENT_EVIDENCE for nerve regeneration in healthy users or clinical neuropathy contexts.
In a rat stroke model J-147 plus clot-dissolving therapy reduced infarct volume and hemorrhage (Jin et al. 2022). Recovery-relevant, but early and preclinical.
Metformin can complicate neuropathy through B12 depletion. Ballal 2025 supports ongoing concern around long-term metformin, B12 deficiency, and peripheral neuropathy monitoring.
NAD+ supports neuronal health and NADPARK suggests neuroprotective potential, but direct human nerve-regeneration evidence for NR remains limited.
Tirzepatide may improve diabetes risk factors that contribute to neuropathy progression. There is no direct nerve regeneration trial. Existing benefits are preventive or metabolic, not regenerative. Score low and frame as metabolic…
One animal repair signal exists: Weiss 2021 studied stem cells, G-CSF, and/or dihexa in a rat sciatic nerve damage-repair model. This is not standalone human nerve-regeneration evidence.
Animal neurogenesis data do not equal nerve-regeneration evidence. No peripheral neuropathy, nerve crush, diabetic neuropathy, or radiculopathy human RCT supports clinical use.
Preclinical nerve-repair data exist, but human clinical evidence is thin.
TRT has limited human evidence for nerve regeneration. If neuropathy or nerve injury exists, address glucose, B vitamins, compression, inflammation, rehabilitation, and specialist care first.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 6 of 26 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| PEMF (Pulsed Electromagnetic Field Therapy) | $3–$117 | 20-30 min mat session | Over the counter |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| ARA-290 (Cibinetide) | Not priced yet | ||
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Essential Amino Acids | Not priced yet | ||
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| J-147 | Not priced yet | ||
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Dihexa | $30–$60 | 8-12 mg/day sublingual | Research use only |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
Head-to-head reports and category rankings that name a winner on this use case.
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
Semax scores 7.0–7.5/10 and cerebrolysin 6.0–6.5/10. Semax wins cognition, neuroplasticity and nerve regeneration, costs an estimated $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.0–7.5/10 against dihexa's 4.0–4.5/10, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
BPC-157, at 7.5–8.0 out of 10 for nerve regeneration. Vasireddi 2025 anchors the most relevant signal.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 4.5–5.0 out of 10 for nerve regeneration.
Dihexa scores 3.5–4.0 out of 10 for nerve regeneration but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
26 of the 85 interventions evaluated for nerve regeneration score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
